Trials / Active Not Recruiting
Active Not RecruitingNCT07063758
A Biomarker Study to Predict Treatment Outcomes of Enfortumab Vedotin in Advanced Urothelial Carcinoma
Biomarker Studies to Predict Treatment Outcomes of Enfortumab Vedotin in Advanced Urothelial Carcinoma
- Status
- Active Not Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 200 (estimated)
- Sponsor
- National Taiwan University Clinical Trial Center · Academic / Other
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to find biological markers that help predict how patients with advanced urothelial carcinoma respond to treatment with enfortumab vedotin (EV) or EV-based combination therapies. Since EV can cause significant side effects and is costly, identifying markers such as nectin-4 and related proteins in tumor tissue and blood may help doctors personalize treatment plans. The investigators will enroll about 100 patients receiving EV and compare them to another 100 patients treated with standard chemotherapy. By studying tissue samples and blood at different times, the investigators hope to discover which markers best indicate treatment success or risks. This research could lead to better, safer treatments tailored to each patient's biology.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Biomarker Analysis | Tumor tissue and serum samples will be collected and analyzed to evaluate the expression of membranous Nectin-4, ADAM10/17, and levels of soluble Nectin-4 (sNectin-4) as predictive biomarkers in patients with advanced urothelial carcinoma receiving standard therapies. |
Timeline
- Start date
- 2025-04-01
- Primary completion
- 2029-09-30
- Completion
- 2029-12-31
- First posted
- 2025-07-14
- Last updated
- 2025-07-16
Locations
1 site across 1 country: Taiwan
Source: ClinicalTrials.gov record NCT07063758. Inclusion in this directory is not an endorsement.